darifenacin

Also Known As:

(S)-1-(2-(2,3-dihydro-5-benzofuranyl)ethyl)-alpha,alpha-diphenyl-3-pyrrolidineacetamide; Emselex; Enablex; UK-88525; darifenacin hydrobromide; darifenacin hydrochloride; darifenacine; darifenicin

Networked: 104 relevant articles (11 outcomes, 27 trials/studies)

Relationship Network

Drug Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrrolidines: 115
    - darifenacin: 104
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Benzofurans: 26
      - darifenacin: 104

Experts

1.	Wyndaele, Jean-Jacques: 4 articles (01/2012 - 09/2005)
2.	Ebinger, U: 4 articles (11/2008 - 10/2007)
3.	Foote, Jenelle: 3 articles (12/2011 - 03/2005)
4.	Steel, Michael: 3 articles (07/2008 - 11/2006)
5.	Hegde, Sharath S: 3 articles (01/2008 - 02/2006)
6.	Lheritier, Karine: 3 articles (11/2007 - 05/2006)
7.	Glavind, Karin: 3 articles (11/2006 - 05/2005)
8.	Prous, J R: 3 articles (01/2006 - 07/2004)
9.	Rabasseda, X: 3 articles (01/2006 - 07/2004)
10.	Kralidis, Georg: 3 articles (09/2005 - 03/2005)

Related Diseases

1.	Overactive Urinary Bladder (Overactive Bladder) 11/01/2006 - "To examine, in a 2-year, non-comparative, open-label extension study, the safety, tolerability and efficacy of darifenacin controlled-release (CR) 7.5/15 mg once daily in patients with overactive bladder (OAB) who completed two 12-week randomized, double-blind, placebo-controlled 'feeder' studies. " 05/01/2000 - "The results of ongoing clinical studies with darifenacin are awaited before it can be concluded that selective antagonism of M(3) receptors leads to improved tolerability over existing agents in the treatment of overactive bladder. " 04/01/2008 - "A comparison of the efficacy of darifenacin alone vs. darifenacin plus a Behavioural Modification Programme upon the symptoms of overactive bladder." 09/01/2007 - "These results may explain that the efficacy of darifenacin in overactive bladder symptoms is partly due to bladder afferent desensitization." 12/01/2011 - "This study was conducted to assess time-to-effect with darifenacin in patients with overactive bladder (OAB). "
2.	Urinary Incontinence 01/01/2004 - "In multicentre, randomised, double-blind trials in patients with OAB, darifenacin 7.5 or 15 mg once daily for 12 weeks significantly reduced the frequency of urinary incontinence, frequency of micturition and frequency and severity of urgency versus placebo. " 10/01/2007 - "Mean urgency urinary incontinence episodes (UUIEs) decreased significantly from baseline to Week 12 with both darifenacin (-88.6%) and placebo (-77.9%; p > 0.05), with 70% and 58% patients responding with >or= 50% reductions, respectively (p = 0.021). " 01/01/2004 - "Darifenacin 15 mg once daily for 2 weeks was as effective as oxybutynin 5 mg three times daily at reducing the frequency of urinary incontinence and frequency and severity of urgency in patients with OAB. " 01/01/2021 - "To evaluate change in fecal incontinence symptom severity after 8 weeks of darifenacin therapy in patients with double incontinence-urgency urinary incontinence (UUI) and fecal incontinence. "
3.	Nocturia 05/01/2006 - "Darifenacin significantly reduced the median number of incontinence episodes/week (-68.7, -76.5, and -77.3% from baseline at 7.5, 15, and 30 mg, respectively, vs -46% with placebo, all p < 0.01) and dose relatedly improved micturition frequency, frequency and severity of urgency, nocturia, and bladder capacity. " 11/01/2004 - "Darifenacin is a novel M3 muscarinic selective receptor antagonist for once-daily treatment of overactive bladder (OAB), a highly prevalent, chronic and debilitating disease defined by urinary urgency with or without urge incontinence, usually with increased frequency of micturition and nocturia. "
4.	Irritable Bowel Syndrome (Syndrome, Irritable Bowel) 07/01/2010 - "The efficacy of darifenacin in diarrhea-predominant irritable bowel syndrome should be evaluated."
5.	Stroke (Strokes) 11/01/2021 - "Neurological safety and efficacy of darifenacin and mirabegron for the treatment of overactive bladder in patients with history of cerebrovascular accident: A prospective study." 11/01/2021 - "To evaluate the neurological safety and clinical efficacy of darifenacin and mirabegron in patients with a history of cerebrovascular accident (CVA) who had overactive bladder (OAB) symptoms. "

Related Drugs and Biologics

1.	Tolterodine Tartrate (Detrol)
2.	oxybutynin (Tavor)
3.	Muscarinic Antagonists
4.	Solifenacin Succinate
5.	Muscarinic Receptors (Muscarinic Acetylcholine Receptor)
6.	Cholinergic Agents (Cholinergics)
7.	trospium chloride (Ceris)
8.	mirabegron
9.	fesoterodine
10.	propiverine

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Therapy (Chemotherapy)
3.	Injections
4.	Castration
5.	Duration of Therapy